News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
MEDICREA: 2012 Annual Sales
January 16, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
The MEDICREA Group (FR0004178572-ALMED), a company specialized in the development of innovative surgical technologies for the treatment of spinal pathologies, listed on Alternext by NYSE - Euronext Paris, announces its 2012 annual sales.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
October 23, 2026
·
2 min read
·
Nick Paul Taylor
Immunology and inflammation
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
October 23, 2026
·
1 min read
·
Annalee Armstrong
China
US explores China biotech restrictions, exempts licensing deals
October 23, 2026
·
3 min read
Deals
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
October 23, 2026
·
2 min read
·
Tristan Manalac
